ProfileGDS5678 / 1435906_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 82% 81% 97% 83% 82% 79% 82% 84% 81% 79% 83% 81% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2547485
GSM967853U87-EV human glioblastoma xenograft - Control 26.0175782
GSM967854U87-EV human glioblastoma xenograft - Control 35.7552981
GSM967855U87-EV human glioblastoma xenograft - Control 49.6082397
GSM967856U87-EV human glioblastoma xenograft - Control 56.1156583
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7488282
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4314579
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8936982
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2202584
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7732881
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.4592779
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.211283
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8470381
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.554379